Background {#Sec1}
==========

Tight glycemic control (TGC) was found to decrease the mortality and morbidity in critically ill patients \[[@CR1]\] and it has therefore been recommended as the standard treatment for the duration of the perioperative intensive care unit (ICU) throughout the world. However, subsequent trials have failed to confirm the benefits of this recommendation \[[@CR2], [@CR3]\].

Perioperative hyperglycemia is reported in approximately 20--40% of patients after general surgery \[[@CR4]\] and almost 80% of patients undergoing cardiac surgery \[[@CR5]\]. Several studies in cardiac surgery and general surgery have shown a clear association between perioperative hyperglycemia and adverse clinical outcomes including delayed wound healing, surgical site infections, and prolonged hospital stay \[[@CR4], [@CR6]\]. However, the optimal glucose target during the post-operative period is widely controversial. No significant difference was found between TGC and conventional glycemic control (CGC) when evaluating the variety of complications \[[@CR5], [@CR7], [@CR8]\]. However, another study. \[[@CR9]\] including cardiac surgery patients reported a reduction of postoperative complications in TGC group.

Given the conflicting results and the lack of well-powered studies that support current guideline recommendations, the present study employed meta-analysis to evaluate the current evidence and analyze the association between the strategies of postoperative glycemic control and outcomes in patients undergoing elective surgery.

Methods {#Sec2}
=======

This meta-analysis was performed according to meta-analyses (PRISMA) format guidelines \[[@CR10]\].

Search strategy {#Sec3}
---------------

EMBASE, MEDLINE, and the Cochrane Library were searched electronically by two investigators (Long CHEN and Fang TIAN) for relevant studies, and the following key words were used: "Blood Glucose" "insulin" and "Postoperative Period". The searches were last updated in 16th April 2018. Search strategies are available in Additional file [1](#MOESM1){ref-type="media"}. Two investigators (Long CHEN and Fang TIAN) independently screened the titles and abstracts to exclude irrelevant articles. Then, they reviewed the full-text articles to ensure all relevant articles had been included. A third author resolved any controversies.

Study selection and data extraction {#Sec4}
-----------------------------------

We only included randomized controlled trials (RCTs) with surgery patients who had received postoperative TGC. Specific eligibility criteria were as follows: (a) published in English; (b) treatment with postoperative TGC; and (c) the study documented any endpoints including infection or mortality. Two authors (Long CHEN and Fang TIAN) evaluated all records according to the above eligibility criteria (Table [1](#Tab1){ref-type="table"}). We abstracted the year of publication, sample size, type of surgery, population type (adult or infant), patient age, gender, history of diabetes, baseline BG (blood glucose level), time of TGC intervention (only during the post-operative or intra-operative plus post-operative), target BG and trigger BG for intervention, any insulin infusion protocol, and reported clinical outcomes.Table 1Main characteristics of the included trialsFirst authorType of surgeryPatient typeSampleTime of interventionInsulin infusion protocolMean age (mean ± SD, year)Male (%)BMI(mean ± SD)TGC/CGCTGCCGCTGCCGCTGCCGCVan Den et al. (2001)various surgeriesadult1548(765/783)postoperativeYes63.4 ± 13.662.2 ± 13.9717126.2 ± 4.425.8 ± 4.7Salah M et al. (2013)cardiac surgeryadult100(50/50)Intra + post operativeYes46.0 ± 9.049.0 ± 8.0607028.0 ± 0.826.0 ± 2.0Konstantinos et al. (2013)cardiac surgeryadult212(105/107)postoperativeYes64.9 ± 11.566.9 ± 11.1666827.8 ± 4.428.0 ± 3.9Amisha et al. (2017)liver transplantationadult164(82/82)postoperativeYes58.1 ± 8.056.9 ± 7.6656530.3 ± 6.030.0 ± 6.6Rehong Zheng et al. (2010)cardiac surgeryadult100(50/50)Intra + post operativeYes43.3 ± 11.744.0 ± 11.54846Raquel Pei Chen Chan et al. (2009)cardiac surgeryadult108(54/55)Intra + post operativeYes57.0 ± 12.058 ± 12435624.0 ± 3.426.0 ± 4.9Shou-gen Cao et al. (2011)elective radical gastrectomy with D2 lymphadenectomyadult248(125/123)postoperativeYes58.5 ± 8.159.9 ± 7.6676420.8 ± 2.121.2 ± 2.1Shou-gen Cao et al. (2011)elective radical gastrectomy with D2 lymphadenectomyadult179(92/87)postoperativeYes58.2 ± 6.359.4 ± 7.3303421.1 ± 2.022.2 ± 2.6Takehiro Okabayashi et al. (2014)hepatectomy or pancreatectomyadult447(222/225)Intra + post operativeNo66.7 ± 10.166.4 ± 10.4646723.3 ± 3.623.1 ± 3.4Ehab A. Wahby et al. (2016)cardiac surgeryadult135(67/68)Intra + post operativeNo54.99 ± 6.4956.40 ± 7.797368Federico Bilotta et al. (2009)Neurosurgicaladult483(241/242)postoperativeYes57.3 ± 11.956.9 ± 12.76352Shalin P. Desai et al. (2012)cardiac surgeryadult189(91/98)postoperativeYes62.5 ± 10.262.8 ± 9.58980Federico Bilotta et al. (2007)Intracranial Aneurysm Clippingadult78(40/38)Intra + post operativeYes53.0 ± 16.052.0 ± 15.03032Michael SD Agus et al. (2012)cardiac surgerybirth to 36 months980(490/490)postoperativeYes4.3(1.8--9.7) months4.9(2.3--10.8) months5156Harold L et al. (2011)cardiac surgeryadult82(40/42)Intra + post operativeYes63 ± 965 ± 96576First authorHistory of diabetes (%)Baseline blood glucose (mean ± SD, mg/dL)Target blood glucose(mean ± SD, mg/dL)Trigger blood glucose(mean ± SD, mg/dL)Postoperatively maintain blood glucose(mean ± SD, mg/dl)Glucocorti-coids usedpostoperative follow-upJadad ScoreTGCCGCTGCCGCTGCCGCTGCCGCTGCCGCVan Den et al. (2001)131380--110180--200110215103 ± 19153 ± 33Noin-hospital6Salah M et al. (2013)10010080--110110--180110180No6 months2Konstantinos et al. (2013)2631120--160161--200160200153.9 ± 13.9173.9 ± 17.4No30 days or in-hospital1Amisha et al. (2017)2832140180146.4 ± 16.4178.8 ± 24.0Yes1 year4Rehong Zheng et al. (2010)0078.4 ± 3.877.5 ± 2.670--110110No2Raquel Pei Chen Chan et al. (2009)113.4 ± 42.5138 ± 7580--130160--200130200126.7 ± 10.8168.2 ± 28.3No30 days3Shou-gen Cao et al. (2011)0099.0 ± 14.495 ± 1380--110\<  20011020094.5 ± 15.3184.0 ± 16.7No28 days2Shou-gen Cao et al. (2011)100100122.4 ± 10.8126 ± 1380--110180--21511021599 ± 14.4178.2 ± 18No28 days1Takehiro et al. (2014)242680--110140--180110180No1 day2Ehab A. Wahby et al. (2016)100100164.1 ± 12.1167 ± 17110--149150--180Noweaned from mechanical ventilation2Federico Bilotta et al. (2009)1010179 ± 32181 ± 2980--110180--21511021592.3 ± 2.5143.3 ± 20.3Yes6 months6Shalin P. Desai et al. (2012)414590--120121--180No30 days1Federico Bilotta et al. (2007)101180--12080--220Yes6 months5Michael SD Agus et al. (2012)0080--110110112(104--120)121(109--136)Yes30 days6Harold L et al. (2011)100100161 ± 50151 ± 3580--120120--180120180103 ± 17135 ± 12No30 days1*TGC* tight glycemic control, *CGC* conventional glycemic control

Outcomes definition and quality assessment {#Sec5}
------------------------------------------

The primary endpoint for the current review was any postoperative infection including wound infection, pneumonia, urinary tract infection and sepsis. Secondary efficacy outcomes were the duration of mechanical ventilation, length of ICU stay, length of hospital stay (LOS) and other adverse events included the following: (1) short-term mortality (30-day mortality or hospital mortality). Any postoperative mortality including the following outcomes: 30-day mortality, hospital mortality, 6-month mortality and 1-year mortality; (2) neurological dysfunction including delirium, seizures and stroke; (3) acute renal failure that required postoperative CRRT (continuous renal replacement therapy); and (4) hypoglycemia, which was defined as a BG \< 70 mg/dL, and the reported severe hypoglycemia (BG \< 40 mg/dL).

Quality of the included studies {#Sec6}
-------------------------------

The quality assessment of studies was independently performed by two investigators (Long CHEN and Fang TIAN) and the Jadad scale was used to assess the methodological quality of individual studies \[[@CR11]\]. These evaluative criteria included the generation of allocation sequence (2 points), allocation concealment (2 points), investigator blindness (2 points), description of withdrawals and drop-outs (1 points), and the efficacy of randomization (2 points) (Additional file [2](#MOESM2){ref-type="media"}). The discrepancies were resolved by a third author.

Data synthesis and analysis {#Sec7}
---------------------------

The statistical analysis was performed using STATA (Version 12.0). Dichotomous data were expressed as the risk ratio (relative risk \[RR\]) with 95% confidence interval (CI). Data were pooled using a random-effects model (M-H heterogeneity). Statistical heterogeneity was tested by the *I*^2^ statistic and the χ2 test and heterogeneity was considered to be significant when values *I*^2^ \> 50% and *p* ≤ 0.05. Subgroup analyses and meta-regression analyses were applied to detect the potential sources of heterogeneity. Sensitivity analysis was performed to assess the stability of the results. Publication bias was evaluated by Egger's and Begg's test, but it was not performed as the number of included studies was less than10 \[[@CR12]\]. All reported *p* values were two-tailed and values of less than 0.05 were considered to be statistically significant.

Sample size calculation and power analysis {#Sec8}
------------------------------------------

Previous study showed a significant benefit for an intensive compared with a conventional glucose control protocol in reducing post-operative infection (OR 0·43, 0·29 to 0·64), but no significant benefit of death was found (OR 0·74, 0·45 to 1·23) \[[@CR13]\]. A two-tailed power analysis with 0.80 power and an α of 0.05 was used. The post-operative infection and short-term mortality in CGC group was 15.8 and 5.4% respectively, with an estimated standard deviation of 249 patients were needed for post-operative infection and 4020 patients were needed for short-term mortality per study group. About 2233 patients per group were included in the study so the analysis was underpowered to identify an effect of TGC on mortality. Analysis was computed using GPower 3.1.9.2 Software.

Results {#Sec9}
=======

Study selection and characteristics {#Sec10}
-----------------------------------

Our search strategy identified 4191 articles. After screening the titles and abstracts, 4119 articles were excluded. The remaining 72 articles underwent a full-text review, although the study by van den Berghe et al. included adults receiving mechanical ventilation who were admitted to intensive care unit (which included mainly surgical patients (about 92%) and 62.5% had undergone cardiac surgery), because of the importance of this study, we still included it in our meta-analysis. Finally a total of 15 articles that had enrolled 5053 patients were finally included in this meta-analysis \[[@CR1], [@CR14]--[@CR27]\] (Fig. [1](#Fig1){ref-type="fig"}). The detailed characteristics of these studies are presented in Table [1](#Tab1){ref-type="table"}. About 1056 (20.9%) patients had diabetes, nine articles of included 15 articles mainly reported cardiac surgery including 3455 patients (68.4%). Among the included 15 articles, eight articles define tight glycemic control and trigger blood glucose as blood glucose ≤110 mg/dL, three articles were ≤ 120 mg/dL, the last four articles were ≤ 130 mg/dL, ≤140 mg/dL, ≤150 mg/dL and ≤ 160 mg/dL respectively. Eight articles only tight control the blood glucose postoperatively, the other seven articles were during intra and post operative period. The average Jadad Score of the studies included in the meta-analyses was 2.9, only five studies have exceeded 4.Fig. 1Flowchart of the study search, selection and inclusion process

Primary outcomes {#Sec11}
----------------

### Risk of postoperative infection {#Sec12}

Fourteen studies (*n* = 4952) compared the effectiveness of TGC versus CGC with respect to postoperative infection. These studies revealed that the risk of total postoperative infection (9.4% vs. 15.8%; RR 0.586, 95% CI 0.504 to 0.680, *p* \<  0.001; Fig. [2](#Fig2){ref-type="fig"}) and sepsis (2.7% vs. 4.7%; RR 0.594, 95% CI 0.418 to 0.842, *p* = 0.003) were significantly lower in the TGC group than in the CGC group. The most frequent type of infection in the TGC group and CGC group was wound infection (4.6% vs. 7.2%; RR 0.620, 95% CI 0.422 to 1.910, *p* = 0.015). However, no difference was found in pneumonia (2.0% vs. 2.9%; RR 0.692, 95% CI 0.400 to 1.196, *p* = 0.187) and urinary tract infection (3.6% vs. 4.4%; RR 0.843, 95% CI 0.548 to 1.297, *p* = 0.437). In addition, there was no significant heterogeneity between articles (*I*^2^ \< 50%, *p* \> 0.05; Table [2](#Tab2){ref-type="table"}).Fig. 2Forest plot of the risk of postoperative infection in TGC group versus control group. TGC = tight glycemic control; RR = relative risk; CI = confidence intervalTable 2Postoperative adverse events and other outcomesTGCCGCOverall event rates (%)M-H pooled RRHeterogeneityEventsStudiesN+(%)TotalN+(%)TotalRR/ SMD (95%CI)*pI* ^**2**^ **(%)***p*Infection\[[@CR1], [@CR15]--[@CR27]\]231(9.4%)2464392(15.8%)248812.6%0.586(0.504, 0.680)\<  0.0013.90.407Sepsis\[[@CR1], [@CR19], [@CR20], [@CR23], [@CR25], [@CR26]\]48(2.7%)175382(4.7%)17633.7%0.594(0.418, 0.842)0.003\<  0.0010.945Pneumonia\[[@CR19], [@CR20], [@CR23]--[@CR26]\]22(2.0%)107931(2.9%)10782.5%0.692(0.400, 1.196)0.187\<  0.0010.511Urinary tract infection\[[@CR19], [@CR20], [@CR23], [@CR25], [@CR30]\]36(3.6%)98843(4.4%)9804.0%0.843(0.548, 1.297)0.437\<  0.0010.682Wound infection\[[@CR19], [@CR20], [@CR22]--[@CR27]\]54(4.6%)118686(7.2%)11886.1%0.620(0.422, 0.910)0.01518.80.287Short-term mortality\[[@CR1], [@CR14]--[@CR22], [@CR24], [@CR27]\]85(3.8%)2233122(5.4%)22594.6%0.692(0.527, 0.909)0.008\<  0.0010.769Any mortality\[[@CR1], [@CR14]--[@CR27]\]159(6.3%)2514204(8.0%)25397.2%0.792(0.653, 0.960)0.018\<  0.0010.738Neurological dysfunction\[[@CR14], [@CR18], [@CR22], [@CR24], [@CR26]\]8(1.1%)75218(2.4%)7611.7%0.499(0.219, 1.137)0.098\<  0.0010.651Acute renal failure\[[@CR1], [@CR22], [@CR24], [@CR26]\]46(3.3%)141378(5.4%)14394.3%0.610(0.359, 1.038)0.06816.00.312Hypoglycemia\[[@CR1], [@CR16]--[@CR20], [@CR22]--[@CR24], [@CR27]\]467(22.3%)2097233(11.0%)211816.6%3.145(1.928, 5.131)\<  0.00181.4\<  0.001Severe hypoglycemia\[[@CR15], [@CR16], [@CR19]--[@CR21], [@CR24], [@CR26]\]34(2.8%)12078(0.7%)12101.7%3.821(1.796, 8.127)\<  0.001\<  0.0010.894ICU stay\[[@CR1], [@CR15], [@CR16], [@CR18], [@CR23], [@CR26], [@CR27]\]−0.428(−0.833, −0.022)0.03996.6\<  0.001Mechanical ventilation\[[@CR1], [@CR15], [@CR16], [@CR18], [@CR23], [@CR26], [@CR27]\]−0.275(−0.695,0.146)0.20196.9\<  0.001LOS\[[@CR15], [@CR16], [@CR18]--[@CR20], [@CR26], [@CR27]\]−0.233(−0.496,0.030)0.08285.4\<  0.001*N*^*+*^ the number of patient with adverse event, *Total* the number of the total patients, *RR* relative risk, *SMD* standardised mean difference, *LOS* length of hospital stay

Sensitivity analysis and publication Bias {#Sec13}
-----------------------------------------

The results of sensitivity analyses showed consistency in the results with the omission of a single article per replication (Additional file [3](#MOESM3){ref-type="media"}: Table S1). A funnel plot of the risk of postoperative infection identified all studies in the 95% confidence limits (Additional file [4](#MOESM4){ref-type="media"}: Figure S1).

### Risk of postoperative short-term mortality {#Sec14}

Of the 15 studies included, 13 studies (*n* = 4492) compared the effectiveness of TGC versus CGC to assess the risk of postoperative short-term mortality. TGC showed a lower risk of postoperative short-term mortality (3.8% vs. 5.4%; RR 0.692, 95% CI 0.527 to 0.909, *p* = 0.008; Fig. [3](#Fig3){ref-type="fig"}) and any postoperative mortality (6.3% vs. 8.0%; RR 0.792, 95% CI 0.653 to 0.960, *p* = 0.018; Additional file [5](#MOESM5){ref-type="media"}: Figure S2) without evidence of heterogeneity between articles (*I*^2^ \<  0.001%, *p* \> 0.05; Table [2](#Tab2){ref-type="table"}).Fig. 3Forest plot of the risk of postoperative short-term mortality in TGC group versus control group. TGC = tight glycemic control; RR = relative risk; CI = confidence interval

Sensitivity analysis and publication Bias {#Sec15}
-----------------------------------------

Sensitivity analyses showed that the result was mainly influenced by the study of van den Berghe when eliminating one single study per replication (Additional file [6](#MOESM6){ref-type="media"}: Table S2). A funnel plot of the risk of postoperative short-term mortality revealed that no included studies exceeded the 95% confidence limits (Additional file [7](#MOESM7){ref-type="media"}: Figure S3). Begg's (*p* = 0.533 for short-term mortality and *p* = 0.951 for any postoperative mortality; Additional file [8](#MOESM8){ref-type="media"}: Figure S4A) and Egger's test (*p* = 0.741 for short-term mortality and *p* = 0.814 for any postoperative mortality; Additional file [8](#MOESM8){ref-type="media"}: Figure S4B) did not identify significant publication bias.

### Risk of postoperative neurological dysfunction and acute renal failure {#Sec16}

Only five (*n* = 1513) and four (*n* = 2852) articles reported postoperative neurological dysfunction and postoperative acute renal failure respectively. No significant difference was observed in postoperative neurological dysfunction (1.1% vs. 2.4%; RR 0.499, 95% CI 0.219 to 1.137, *p* = 0.098) and postoperative acute renal failure (3.3% vs. 5.4%; RR 0.610, 95% CI 0.359 to 1.038, *p* = 0.068), and no significant heterogeneity was observed between articles (*I*^2^ \< 50%, *p* \> 0.05; Table [2](#Tab2){ref-type="table"}). In addition, sensitivity analyses revealed a consistency of the results based on the omission of a single article at a time for acute renal failure, but not for neurological dysfunction (Additional file [9](#MOESM9){ref-type="media"}: Table S3, Additional file [10](#MOESM10){ref-type="media"}: Table S4). Publication bias analysis was not performed as the number of included studies was less than10 \[[@CR12]\].

### Risk of postoperative hypoglycemia {#Sec17}

Eleven (*n* = 4215) studies compared the safety of TGC versus CGC to assess the risk of postoperative hypoglycemia. We observed more patients experiencing postoperative hypoglycemia (22.3% vs. 11.0%; RR 3.145, 95% CI 1.928 to 5.131, *p* \<  0.001; Fig. [4](#Fig4){ref-type="fig"}) and severe hypoglycemia (2.8% vs. 0.7%; RR 3.821, 95% CI 1.796 to 8.127, *p* \<  0.001; Additional file [11](#MOESM11){ref-type="media"}: Figure S5) in the TGC group as compared to the CGC group. No significant heterogeneity was observed respect to severe hypoglycemia (*I*^2^ \<  0.001%, *p* = 0.894), however, there was significant heterogeneity between articles with a corresponding *I*^2^ of 81.4% (*p* \<  0.001) with respect to postoperative hypoglycemia (Table [2](#Tab2){ref-type="table"}).Fig. 4Forest plot of the risk of postoperative hypoglycemia in TGC group versus control group. TGC = tight glycemic control; RR = relative risk; CI = confidence interval

Sensitivity analysis and publication Bias {#Sec18}
-----------------------------------------

Sensitivity analyses revealed that there was no significant heterogeneity of postoperative hypoglycemia (*I*^2^ = 33.9%, *p* = 0.137 Additional file [12](#MOESM12){ref-type="media"}: Table S5) when we omitted Federico Bilotta's study of neurosurgical patients. The result was consisted with a significant higher rate of postoperative hypoglycemia in the TGC groups (13.0% vs. 4.3%; RR 3.361, 95% CI 2.311 to 4.890, *p* \<  0.001; Additional file [12](#MOESM12){ref-type="media"}: Table S5). A funnel plot of the risk of postoperative hypoglycemia identified two studies beyond the 95% confidence limits (Additional file [13](#MOESM13){ref-type="media"}: Figure S6).

Sensitivity analyses showed consistency in the results of severe hypoglycemia with the omission of a single article per replication (Additional file [14](#MOESM14){ref-type="media"}: Table S6).

Subgroup analysis and meta-regression of postoperative hypoglycemia {#Sec19}
-------------------------------------------------------------------

Then, subgroup analyses and meta-regression were further applied to examine the sources of the heterogeneity. In the subgroup analyses, we found that the type of surgery, but not preoperative diabetes, the type of patient, the time of intervention, the trigger of blood glucose level, and the use of glucocorticoids in the hospital, could explain the heterogeneity (Additional file [15](#MOESM15){ref-type="media"}: Table S7).

However, the result of meta-regression could not identify that the type of surgery was the source of the heterogeneity. The use of glucocorticoids in the hospital was seem to be the source of the observed heterogeneity, but factors such as preoperative diabetes, the type of patient, the time of intervention, trigger of blood glucose level, the mean age, the sample size and the quality of the study did not seem to be the source of the observed heterogeneity (Additional file [16](#MOESM16){ref-type="media"}: Table S8).

### Length of ICU stay and hospitalization {#Sec20}

About half of the included studies reported duration of mechanical ventilation, length of ICU stay and hospitalization. TGC showed less length of ICU stay (SMD, − 0.428 days; 95% CI, − 0.833 to − 0.022 days; *p* = 0.039, Additional file [17](#MOESM17){ref-type="media"}: Figure S7), but TGC showed neutral effect on postoperative duration of mechanical ventilation (SMD, − 0.275 h; 95% CI, − 0.695 to 0.146 h; *p* = 0.201, Additional file [18](#MOESM18){ref-type="media"}: Figure S8) and length of hospitalization (SMD, − 0.233 days; 95% CI, − 0.496 to 0.030 days; *p* = 0.082, Additional file [19](#MOESM19){ref-type="media"}: Figure S9) (Table [2](#Tab2){ref-type="table"}). In the sensitivity analysis, we found significant heterogeneity between the studies (Additional file [20](#MOESM20){ref-type="media"}: Table S9, Additional file [21](#MOESM21){ref-type="media"}: Table S10, Additional file [22](#MOESM22){ref-type="media"}: Table S11).

Subgroup analysis and meta-regression of ICU stay and hospitalization {#Sec21}
---------------------------------------------------------------------

The results of the subgroup analyses and meta-regression analyses revealed that the type of surgery, preoperative diabetes, type of patient, time of intervention, trigger of blood glucose level and use of glucocorticoids in hospital, the year of publication, the mean age, the sample size, and the quality of the study could not identify the heterogeneity; thus, heterogeneity persisted between the included articles (Additional file [23](#MOESM23){ref-type="media"}: Table S12, Additional file [24](#MOESM24){ref-type="media"}: Table S13, Additional file [25](#MOESM25){ref-type="media"}: Table S14, Additional file [26](#MOESM26){ref-type="media"}: Table S15, Additional file [27](#MOESM27){ref-type="media"}: Table S16, Additional file [28](#MOESM28){ref-type="media"}: Table S17).

Discussion {#Sec22}
==========

In the current meta-analysis of randomized trials, we found that when compared to CGC, TGC immediately after surgery significantly reduces total postoperative infection rates and short-term mortality. However, it might limit conclusion regarding the efficacy of TGC for short-term mortality in sensitivity analyses. The patients in the TGC group experienced a significant higher rate of postoperative hypoglycemia. TGC had a neutral effect on the risk of postoperative neurological dysfunction and acute renal failure in patients undergoing surgery. Although there was significant heterogeneity of hypoglycemia between studies, which was primarily caused by the study of Federico Bilotta et al., the pooled RR still derived the same results after omitting this study.

There was still some controversy on the positive effects of TGC in reducing postoperative infection. Some meta-analysis found that intra-operative TGC \[[@CR28]\] or using a TGC strategy in the perioperative period (\< 150 mg/dl) \[[@CR13]\] decreased the infection rate when compared to the conventional therapy; however, other meta-analyses have reported negative effects \[[@CR29], [@CR30]\]. Furthermore, most of those studies just focused on cardiac surgery. A recent retrospective analysis \[[@CR31]\] found that the basal + premeal insulin regimen was associated with a reduced rate of postoperative infective complications than the premeal insulin alone therapy, without increasing the number of severe hypoglycemic events. These results suggest that type of treatments more than levels of glycemic controls might have on beneficial effect these outcomes. This meta-analysis has shown that TGC significantly reduced total postoperative infection, wound infection and sepsis regardless of whether TGC was commenced during or after surgery, but no difference was found in pneumonia and urinary tract infection. This study may suggest that TGC should be administrated especially in those with high postoperative infection risk.

Our meta-analysis further supported the study of van den Berghe \[[@CR1]\] that perioperative TGC reduce the rates of postoperative short-term mortality, but sensitivity analyses showed a negative result when eliminating the study of van den Berghe. It might limit conclusion regarding the efficacy of TGC for mortality. Another meta-analysis \[[@CR32]\] also found that moderate perioperative glycemic control (BG 150--200 mg/dL) was associated with lower postoperative mortality and stroke in patients with diabetes, whereas no additional benefit was found in a stricter glycemic control group (BG \< 150 mg/dL). We should also note that this meta-analysis not only includes randomized studies, but also retrospective studies. A recent retrospective study analyzed a large database of patients in critical care units \[[@CR33]\] and found that TGC (80--110 mg/dL) was associated with the lowest mortality. However, previous meta-analysis found that perioperative TGC did not reduce the rates of short-term mortality in ICU settings \[[@CR29]\] or in various hospital settings \[[@CR28], [@CR34]\] when compared to the conventional therapy. In the NICE-SUGAR trial (Normoglycemia in Intensive Care Evaluation-Survival Using Glucose Algorithm Regulation trial), 6104 critically ill patients in intensive care units (ICUs) were randomized to an intensive blood glucose control (81--108 mg/dL) or conventional glucose control (\< 180 mg/dL) group. It showed that TGC actually increased 90-day mortality and hypoglycemia compared to a more liberal glucose target in the ICU setting \[[@CR2], [@CR3]\]. Recently, in the GLUCO-CABG trial \[[@CR5]\], CABG patients were randomized to TGC (100 to 140 mg/dL) and CGC (141 to 180 mg/dL) groups just in the ICU. The two groups had no significant difference in complications rates of mortality, wound infection, acute kidney injury, or other outcomes, and in the incidence of hypoglycemia or length of hospital stay.

Most studies \[[@CR8], [@CR9]\] and meta-analysis \[[@CR29], [@CR32]\] found a neutral effect of TGC on other clinical outcomes including neurological dysfunction, acute renal failure and length of hospital stay; our result further supported those findings. Our finding was not consistent with the clinical practice guideline from the American College of Physicians \[[@CR30]\] that they found TGC was not associated with a reduction of ICU stay in the mixed medical intensive care unit/surgical intensive care unit environment. Another recent study \[[@CR9]\] found that only nondiabetic cardiac surgery patients, but not patients with diabetes, could gain significant benefit of postoperative complications from intraoperative TGC.

The major harm of TGC was that it might increase hypoglycemia, especially in critically ill patients \[[@CR2], [@CR35], [@CR36]\]. The study by Finfer S et al. found that intensive glucose control leads to moderate and severe hypoglycemia in critically ill patients \[[@CR2]\]. Our finding was also consistent with many studies \[[@CR13]\] and other meta-analysis \[[@CR29], [@CR34]\], which have also noted that using a TGC protocol in the perioperative period increased the risk of hypoglycemia, but without a significant increase in serious adverse events in various hospital settings. However, a recent meta-analysis \[[@CR28]\] that found intraoperative insulin therapy may not increase the rate of hypoglycemia. The consequences of hypoglycemia in hospitalized patients remain unclear as few studies report clinical adverse effects and explain how hypoglycemia harms patients in the long-term consequences. The study of Finfer S \[[@CR2]\] has confirmed that both of moderate and severe hypoglycemia was associated with an increased risk of death in critically ill patients, however, others argued \[[@CR37]\] that hyperglycemia was more similar to a signal of illness severity rather than the cause of clinical adverse outcomes. Indeed, the hyperglycemia level was related to the activation of the stress response.

The conflict of the results between the present meta-analysis and others can be explained by different inclusion criteria, patient characteristics, time of TGC, type of treatments, hospital setting, and the definition of hypoglycemia. Furthermore, the markedly variation in blood glucose target levels, the protocols of glucose monitoring and managing among studies may also influence the results.

There are some strengths of this study. For the first time, the present meta-analysis was conducted to evaluate the association between postoperative glycemic control and outcomes in patients undergoing elective surgery. Second, we have included the most rigorous analysis of TGC studies to date and conducted a comprehensive meta-analysis to elevate the effect of postoperative TGC on outcomes. However, high-quality evidence to support the routine use of postoperative TGC is still lacking.

Limitations {#Sec23}
-----------

There are some limitations in this meta-analysis. First, the source data were extracted from diverse types of surgery and glycemic targets. In addition, there were variations in the timing of the intervention (postoperative versus intra-operative plus post-operative). Finally, the number of eligible studies was small; thus the results were likely biased. This may underestimate the benefit of TGC. Despite these differences, no significant heterogeneity was observed between studies with respect to the primary endpoint and most other outcomes and our results were consistent in the sensitivity analyses.

Conclusions {#Sec24}
===========

The results of this study show that TGC immediately after surgery significantly reduces total postoperative infection rates and short-term mortality. However, it might limit conclusion regarding the efficacy of TGC for short-term mortality in sensitivity analyses. The patients in the TGC group experienced a significant higher rate of postoperative hypoglycemia. TGC had a neutral effect on the risk of postoperative neurological dysfunction and acute renal failure as compared to CGC. This study may suggest that TGC should be administrated under close glucose monitoring in patients undergoing surgery, especially in those with high postoperative infection risk. In addition, large, prospective, randomized and high quality trials on the efficacy and safety of TGC in the postoperative period are needed to investigate the ideal BG target to optimize clinical outcomes and minimize adverse events in patients undergoing surgery.
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BG

:   Blood glucose level

CGC

:   Conventional glycemic control

CI

:   Confidence interval

CRRT

:   Continuous renal replacement therapy

ICU

:   Intensive care unit

LOS

:   Length of hospital stay

RR

:   Relative risk

SMD

:   Standardised mean difference

TGC

:   Tight glycemic control
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